Dual GIP/GLP-1 agonist · LY3298176
A 39-amino-acid acylated peptide with dual activity at GIP and GLP-1 receptors. The most-cited dual incretin reference compound in current metabolic-research literature.
| Compound | Tirzepatide |
| Research category | Metabolic Research |
| Available sizes | 2mg, 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 50mg, 60mg, 70mg, 80mg, 90mg, 100mg, 110mg, 120mg |
| Pricing | From £50 |
| Format | Lyophilised powder in sealed vial & pre-reconstituted pen |
| Purity | >99% by HPLC (Janoshik Analytical, batch-verified) |
| Intended use | In-vitro laboratory research only. Not for human consumption. |
Reference data drawn from public databases (PubChem, UniProt) and peer-reviewed literature. For research and laboratory characterisation only.
| Compound class | Synthetic 39-amino-acid dual GIP / GLP-1 receptor agonist peptide |
| Molecular formula | C225H348N48O68 |
| Molecular weight | 4813.5 g/mol |
| CAS Registry Number | 2023788-19-2 |
| PubChem CID | 156588324 |
| Number of residues | 39 |
| Amino acid sequence | YXEGTFTSDYSIYLDKQAAXEFVNWLLAGGPSSGAPPPS-NH2 (X = α-aminoisobutyric acid) |
| Receptor / mechanism | Dual agonist: GIP receptor (high affinity) + GLP-1 receptor (high affinity). |
| Reported half-life | Reported ~120 hours in primate models in the published literature. |
| Solubility | Lyophilised powder reconstitutes in bacteriostatic water for laboratory use. |
| Storage (lyophilised) | Stable at 2–8 °C in lyophilised form for 24+ months. |
| Storage (reconstituted) | Reconstituted: store at 2–8 °C, use within 28 days. |
| Clinical / regulatory status | Approved by FDA (2022) for type-2 diabetes / obesity research applications. |
Tirzepatide is a synthetic 39-amino-acid peptide characterised in the literature as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Supplied as lyophilised powder for in-vitro research use only.
The above describes how this compound is characterised in the published peer-reviewed literature. It is not a claim about effects in humans.
Tirzepatide is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. For laboratory reconstitution, add the desired volume of diluent (typically bacteriostatic water) slowly down the side wall of the vial. Swirl gently until fully dissolved - do not vortex or shake. Store reconstituted solutions at 2–8 °C and use within 4–6 weeks.
Use our Reconstitution Volume Calculator to compute the resulting mg/ml concentration.
| State | Temperature | Shelf life |
|---|---|---|
| Lyophilised | 2–8 °C or −20 °C | Up to 24 months |
| Reconstituted | 2–8 °C | 4–6 weeks typical |
Every batch of Tirzepatide we supply is independently HPLC-verified by Janoshik Analytical. Where a Janoshik report has been issued for the current batch it is supplied with the order and carries a unique verification key that can be authenticated against Janoshik's records. Reported purity is consistently above 99%.
Researchers working with Tirzepatide often work alongside the following compounds in the preclinical literature:
References are independent peer-reviewed sources. Black & White Peptides Ltd is not affiliated with these publications.